par Rozencweig, Marcel 
;Heuson, Jean-Claude ;Bila, S.;L'Hermite, Marc ;Robyn, Claude
Référence European journal of cancer, 9, 9, page (657-664)
Publication Publié, 1973
;Heuson, Jean-Claude ;Bila, S.;L'Hermite, Marc ;Robyn, Claude Référence European journal of cancer, 9, 9, page (657-664)
Publication Publié, 1973
Article révisé par les pairs
| Résumé : | The effects of cyclic imide derivatives (CG 603 and CG 809), of l-dopa and of 2-Br-α-ergocryptine (CB 154) on serum prolactin levels were studied in postmenopausal women. A single oral dose of l-dopa (500 mg) or CB 154 (5 mg) was followed by a significant decrease in serum prolactin levels. After l-dopa, this decrease lasted an average of 4 hr and was followed by a rebound at 8 hr. After CB 154, the decrease lasted at least 8 hr. Single doses of CG 603 (660 mg) or CB 809 (2 g) failed to influence prolactin levels. The effects of chronic oral administration of either l-dopa or CB 154 were also studied. The pretreatment circadian rhythm of serum prolactin levels, as determined on samples taken every 2 hr, served as control: it was characterized by a high and broad peak occurring during the night. l-dopa, 500 mg given every 6 hr, produced a saw-toothed effect with short-lasting falls after each dose, followed by sharp rebounds. The mean 24-hr levels on days 9 and 14 of treatment were 94% and 72% of the mean control value. CB 154, 5 mg three times daily, induced a profound and sustained decrease in prolactin levels, with complete abolition of the circadian rhythm. The mean 24-hr levels on days 13 and 17 of treatment were 27% and 33% of the mean control value. These experiments show that CB 154 is an effective prolactin-inhibiting agent although complete suppression was not achieved. l-dopa was effective though definitely less so than CB 154. Reported successes of the former and failures of the latter to induce remissions in advanced breast cancer are discussed with regard to the present data. © 1973. |
